Company Profile
Immuneering Stock Price, News & Analysis
- Ticker:
- IMRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.46 USD (+1.59%)
Close
Last updated: August 6, 2026
277M USD
Market cap
Why the stock is moving
The latest monitored headline was “Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates”. IMRX was little changed in the corresponding trading session, closing at $4.39 on Aug 5, 2026.
Company overview
Deep Cyclic Inhibitors
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity.
Atebimetinib
Atebimetinib is an oral, once-daily MEK inhibitor and Immuneering's lead candidate. The drug is designed for combination use across multiple solid tumors rather than as a narrowly targeted monotherapy.
Pancreatic Cancer Development
The global randomized MAPKeeper 301 pivotal Phase 3 trial evaluates atebimetinib with modified gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. The pipeline also includes additional atebimetinib combinations and preclinical programs.
Future catalysts
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a.... That matters because the company is now talking about Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now. That is the piece most likely to shape sentiment in the near term.
Recent news
- 01
- 02
- 03
Immuneering Corporation Announces Grants of Inducement Awards
Source: Immuneering
- 04
Immuneering Appoints Andrew Gengos as Chief Financial Officer
Source: Immuneering
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immuneering (IMRX)?
Immuneering (IMRX) most recently closed at 4.46 USD, a +1.59% move versus the previous session.
What is the market cap of Immuneering (IMRX)?
Immuneering currently has a market capitalization of 277M USD on BioPharmSignal.
What does Immuneering do?
Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily MEK inhibitor and...
On which exchange is IMRX stock listed?
Immuneering (IMRX) is associated with NASDAQ, United States, Biopharma.
What is atebimetinib?
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a....
Which conditions is Immuneering targeting with atebimetinib?
Immuneering is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immuneering describe recent progress with atebimetinib?
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a....
What is Deep?
Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers.